The Quantellect read.As of Nov 19, 2026, 3 active firms cover Nanobiotix: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $30.00 to $64.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $46.67 sits 73% above the current $27.01. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.00 next quarter toward $-0.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$46.67
+72.8% upside
Average target across 3 active firms as of Nov 19, 2026 vs $27.01 current
Highest Target$64.00
Average Target$46.67
Lowest Target$30.00
Detailed analyst forecasts for NBTX
Showing 1–4 of 4 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate NBTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NBTX EPS & revenue forecast
EPS · NEXT QUARTER
$0.00
Range $0.00 – $0.00 · 0 analysts
Next period, 0 analysts expect Nanobiotix to earn $0.00 a share (range $0.00 – $0.00), versus — a year earlier. Full-year consensus is $-0.54, growing to $-0.15 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 0 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $29.4M, rising to $44.4M next year.
Top analysts covering Nanobiotix
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NBTX.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$36.00+33.3% to target
Overall win rate
53%
+ Follow
#2
Jonathan Chang
Leerink Partners
Buy
$46.00+70.3% to target
Coverage
—
+ Follow
#3
PJ
Paul Jeng
Guggenheim
Buy
$64.00+136.9% to target
Coverage
—
+ Follow
#4
DD
David Dai
UBS
Neutral
$30.00+11.1% to target
Coverage
—
+ Follow
#5
CB
Colin Bristow
UBS
Neutral
$30.00+11.1% to target
Coverage
—
+ Follow
NBTX stock forecast FAQ
What is NBTX's average 12-month price target?+
The 3 active firms with a live target average $46.67 for Nanobiotix over the next 12 months, ranging from a $64.00 high to a $30.00 low, as of Nov 19, 2026.
Is NBTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NBTX?+
The Street-high target is $64.00 (Guggenheim), and the Street-low is $30.00 (UBS). The average of all 3 active-firm targets is $46.67.
How many active Wall Street firms cover NBTX?+
3 active firms have a recognized rating on Nanobiotix as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NBTX?+
Among analysts who currently cover NBTX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $36.00 target.
What is Nanobiotix's projected EPS for next quarter?+
The consensus estimate is $0.00 per share (range $0.00 – $0.00) across 0 analysts. Full-year EPS is projected at $-0.54, rising to $-0.15 the following year.
How much revenue is Nanobiotix expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $29.4M, growing to $44.4M next year.
Have analysts been upgrading or downgrading NBTX lately?+
As of Nov 19, 2026, 2 of 3 active firms rate NBTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NBTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.